Bayer Schering strengthens cancer imaging tech with Hamamatsu pact
This article was originally published in Clinica
Bayer Schering Pharma has boosted its portfolio of molecular imaging agents after gaining exclusive global rights to a group of molecules that have been designed to bind to malignant tumour cells. Bayer gained the rights to research, develop and commercialise the molecules for use in the early detection of cancer from imaging and measuring equipment firm Hamamatsu Photonics (Hamamatsu, Japan) for an undisclosed fee. According to Berlin, Germany-based Bayer, the molecules can be combined with positron emission tomography (PET) to potentially improve the diagnosis of a range of different cancers.